Growth Metrics

Adma Biologics (ADMA) Total Non-Current Liabilities (2016 - 2025)

Adma Biologics' Total Non-Current Liabilities history spans 14 years, with the latest figure at $146.9 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 5.47% year-over-year to $146.9 million; the TTM value through Dec 2025 reached $146.9 million, up 5.47%, while the annual FY2025 figure was $146.9 million, 5.47% up from the prior year.
  • Total Non-Current Liabilities reached $146.9 million in Q4 2025 per ADMA's latest filing, up from $137.4 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $199.8 million in Q3 2022 to a low of $121.2 million in Q2 2021.
  • Average Total Non-Current Liabilities over 5 years is $165.9 million, with a median of $170.4 million recorded in 2022.
  • Peak YoY movement for Total Non-Current Liabilities: soared 50.32% in 2022, then plummeted 30.3% in 2025.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $134.7 million in 2021, then skyrocketed by 45.63% to $196.1 million in 2022, then dropped by 1.32% to $193.6 million in 2023, then decreased by 28.03% to $139.3 million in 2024, then increased by 5.47% to $146.9 million in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Total Non-Current Liabilities are $146.9 million (Q4 2025), $137.4 million (Q3 2025), and $160.1 million (Q2 2025).